Mr. Hutt, there have been two changes, as I understand it, to the intellectual property regime as it relates to pharmaceuticals. One of them has to do with giving patent right-holders the right of appeal that currently does not exist for patent right-holders but does exist for generic manufacturers.
It has been said this would give all litigants equal appeal rights. If that's the case, how was that unfair?